Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acid, Edetic
2. Acid, Ethylenediaminetetraacetic
3. Acid, Ethylenedinitrilotetraacetic
4. Calcitetracemate, Disodium
5. Calcium Disodium Edetate
6. Calcium Disodium Versenate
7. Calcium Tetacine
8. Chelaton 3
9. Chromium Edta
10. Copper Edta
11. Coprin
12. Dicobalt Edta
13. Dinitrilotetraacetate, Disodium Ethylene
14. Dinitrilotetraacetate, Ethylene
15. Disodium Calcitetracemate
16. Disodium Edta
17. Disodium Ethylene Dinitrilotetraacetate
18. Disodium Versenate, Calcium
19. Distannous Edta
20. Edathamil
21. Edetate Disodium Calcium
22. Edetate, Calcium Disodium
23. Edetates
24. Edetic Acid
25. Edetic Acid, Calcium Salt
26. Edetic Acid, Calcium, Sodium Salt
27. Edetic Acid, Chromium Salt
28. Edetic Acid, Dipotassium Salt
29. Edetic Acid, Disodium Salt
30. Edetic Acid, Disodium Salt, Dihydrate
31. Edetic Acid, Disodium, Magnesium Salt
32. Edetic Acid, Disodium, Monopotassium Salt
33. Edetic Acid, Magnesium Salt
34. Edetic Acid, Monopotassium Salt
35. Edetic Acid, Monosodium Salt
36. Edetic Acid, Potassium Salt
37. Edetic Acid, Sodium Salt
38. Edta
39. Edta, Chromium
40. Edta, Copper
41. Edta, Dicobalt
42. Edta, Disodium
43. Edta, Distannous
44. Edta, Gallium
45. Edta, Magnesium Disodium
46. Edta, Potassium
47. Edta, Stannous
48. Ethylene Dinitrilotetraacetate
49. Ethylene Dinitrilotetraacetate, Disodium
50. Ethylenediaminetetraacetic Acid
51. Ethylenedinitrilotetraacetic Acid
52. Gallium Edta
53. Magnesium Disodium Edta
54. N,n'-1,2-ethanediylbis(n-(carboxymethyl)glycine)
55. Potassium Edta
56. Stannous Edta
57. Tetacine, Calcium
58. Tetracemate
59. Versenate
60. Versenate, Calcium Disodium
61. Versene
1. 139-33-3
2. Edta Disodium Salt
3. Disodium Edetate
4. Edta Disodium
5. Titriplex Iii
6. Disodium Edta
7. Disodium Edta, Anhydrous
8. Cheladrate
9. Ethylenediaminetetraacetic Acid Disodium Salt
10. Disodium Versene
11. Endrate Disodium
12. Sodium Versenate
13. Disodium Salt Of Edta
14. Metaquest B
15. Kiresuto B
16. Chelaplex Iii
17. Complexon Iii
18. Diso-tate
19. Chelaton Iii
20. Versene Na
21. Triplex Iii
22. Chelaton 3
23. Disodium Versenate
24. Edathamil Disodium
25. Trilon Bd
26. Versene Na2
27. Disodium Sequestrene
28. Disodium Tetracemate
29. F 1 (complexon)
30. Disodium Ethylenediaminetetraacetate
31. Sequestrene Sodium 2
32. Ethylenediaminetetraacetic Acid, Disodium Salt
33. Disodium Edta Dihydrate
34. Perma Kleer Di Crystals
35. Edetic Acid Disodium Salt
36. Disodium Edetate Dihydrate
37. Disodium Dihydrogen Ethylenediaminetetraacetate
38. Disodium Ethylenediamine-n,n,n',n'-tetraacetate
39. Glycine, N,n'-1,2-ethanediylbis[n-(carboxymethyl)-, Disodium Salt
40. Edta-na2
41. Edta Disodium Salt (anhydrous)
42. Edetate Disodium Anhydrous
43. Perma Kleer 50 Crystals Disodium Salt
44. Disodium Ethylenediaminetetraacetic Acid
45. Ethylene Diamine Tetraacetic Acid, Disodium Salt
46. Disodium (ethylenedinitrilo)tetraacetate
47. Sodium Ethylenediaminetetraacetate
48. Cbc 50152966
49. Dr-16133
50. Ethylenediaminetetraacetate, Disodium Salt
51. Disodium Diacid Ethylenediaminetetraacetate
52. Mfcd00070672
53. Disodium (ethylenedinitrilo)tetraacetic Acid
54. Trilon B
55. Disodium Dihydrogen(ethylenedinitrilo)tetraacetate
56. Glycine, N,n'-1,2-ethanediylbis(n-(carboxymethyl)-, Disodium Salt
57. Endrate (tn)
58. Chelest B
59. Komplexon Iii
60. Clewat N
61. Disodium Edathamil
62. Zonon D
63. Dotite 2na
64. Selekton B 2
65. Tetracemate Disodium
66. Mavacid Ed 4
67. Na2-edta
68. Disodium Edetate Hydrate
69. Versonol 120
70. Chelest 200
71. Anhydrous Disodium Edetate
72. Veresene Disodium Salt
73. Edetate Disodium, Anhydrous
74. 8nlq36f6mm
75. Ethylenediaminetetraacetic Acid Disodium Salt Solution
76. Ethylenediaminetetraacetic Acid Disodium Salt, 0.050m Standardized Solution
77. Disodium 2-({2-[(carboxylatomethyl)(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetate
78. Chebi:64734
79. Acetic Acid, (ethylenedinitrilo)tetra-, Disodium Salt
80. Nsc-2760
81. Ccris 3658
82. E.d.t.a. Disodique [french]
83. F 1 (van)
84. E.d.t.a. Disodique
85. Nsc-759604
86. Nsc 2760
87. Einecs 205-358-3
88. Unii-8nlq36f6mm
89. Ethylenediamine Tetraacetic Acid Disodium Salt
90. Dinatrium Ethylendiamintetraacetat [czech]
91. Ai3-18049
92. Ethylenebis(iminodiacetic Acid) Disodium Salt
93. Dinatrium Ethylendiamintetraacetat
94. Hsdb 8013
95. Disodium 2-((2-((carboxylatomethyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)acetate
96. (ethylenedinitrilo)-tetraacetic Acid Disodium Salt
97. Na2edta
98. 0.5m Sodium Edta
99. Disodium Edetate (tn)
100. Na2.edta
101. N,n'-1,2-ethanediylbis(n-(carboxymethyl)glycine) Disodium Salt
102. Ec 205-358-3
103. Edta Disodium Salt Anhydrous
104. Chembl1749
105. Dtxsid9027073
106. Disodium N,n'-1,2-ethanediylbis(n-(carboxymethyl)glycine)
107. Disodium Ethylenediamine-tetraacetate
108. Db14600
109. Sb40706
110. E386
111. Ethylenediaminetetracetic Acid Disodium Salt
112. Db-042467
113. Ethylenediaminetetra-acetic Acid Disodium Salt
114. D03945
115. P17519
116. J-007267
117. J-521348
118. Q4532977
119. Glycine, N,n'-1,2-ethanediylbis(n-(carboxymethyl)-, Sodium Salt (1:2)
120. (ethylenedinitrilo)tetraacetic Acid Disodium Salt, Edta Disodium Salt, Edta-na2
121. Disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate
122. Ethylenediaminetetraacetic Acid Disodium Salt, 0.100n (0.050m) Standardized Solution
123. Ethylenediaminetetraacetic Acid Disodium Salt, 0.115n (0.0575m) Standardized Solution
124. Ethylenediaminetetraacetic Acid Disodium Salt, 0.200n (0.1m) Standardized Solution
125. Disodium 2-({2-[(carboxylatomethyl)(carboxymethyl)amino]ethyl(carboxymethyl)amino)acetate
| Molecular Weight | 336.21 g/mol |
|---|---|
| Molecular Formula | C10H14N2Na2O8 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 9 |
| Exact Mass | 336.05455397 g/mol |
| Monoisotopic Mass | 336.05455397 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 336 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Anticoagulants; Chelating Agents; Food Additives
National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)
Endrate (Edetate Disodium Injection, USP) is indicated in selected patients for the emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
Disodium edentate is also used therapeutically as an anticoagulant as it will chelate calcium and prevent the coagulation of blood in vitro. Concentrations of 0.1% w/v are used in small volumes for hematological testing and 0.3% w/v in transfusions.
Rowe, R.C., Sheskey, P.J., Quinn, M.E.; (Eds.), Handbook of Pharmaceutical Excipients 6th edition Pharmaceutical Press, London, England 2009, p. 243
Disodium EDTA is used occasionally to terminate the effects of injected calcium, to antagonize digitalis toxicity, or to suppress tachyarrhythmias. /Former/
Cosmetic Ingredient Expert Review Panel; Final Final Report on the Safety Assessment of EDTA, Calcium, Disodium EDTA, Diammonium EDTA, Dipotassium EDTA, Disodium EDTA, TEA-EDTA, Tetrasodium EDTA, Tripotassium EDTA, Trisodium EDTA, HEDTA, and Trisodium HEDTA. International Journal of Toxicology 21 (S2): 95-142 (2002)
For more Therapeutic Uses (Complete) data for Disodium EDTA (8 total), please visit the HSDB record page.
/BOXED WARNING/ The use of this drug in any particular patient is recommended only when the severity of the clinical condition justifies the aggressive measures associated with this type of therapy.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
Clinical studies of edetate disodium did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
Fatal medication errors have occurred that involve confusion between edetate calcium disodium (calcium EDTA) and edetate disodium (no longer commercially available in the US). Children and adults have mistakenly received edetate disodium instead of edetate calcium disodium; at least 5 deaths have occurred as a result of inadvertent administration of edetate disodium. Although both edetate calcium disodium and edetate disodium are heavy metal antagonists, the 2 drugs were originally approved by the US Food and Drug Administration (FDA) for different uses and have different effects; edetate disodium was formerly FDA approved for use in selected patients for the emergency treatment of hypercalcemia or for the control of ventricular arrhythmias associated with cardiac glycoside toxicity. Use of edetate disodium may result in a substantial, and sometimes fatal, decrease in serum calcium concentrations. In June 2008, FDA withdrew its prior approval for edetate disodium because of safety concerns following a review of the risk-benefit profile of the drug. FDA stated that it was not considering additional action regarding edetate calcium disodium at that time; most of the fatalities following administration of an EDTA drug have involved medication errors in which edetate disodium was administered instead of edetate calcium disodium. FDA has not received reports of any fatalities resulting from the administration of edetate calcium disodium that involve a medication error.
American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011
Edetate Disodium Injection is contraindicated in anuric patients. It is not indicated for the treatment of generalized arteriosclerosis associated with advancing age.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
For more Drug Warnings (Complete) data for Disodium EDTA (22 total), please visit the HSDB record page.
Edetate disodium is indicated for emergency treatment of hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Edetate disodium anhydrous is a polyvalent ion chelator that reduces blood concentrations of calcium or digitalis. It has a long duration of action as patients are generally given 1 daily dose. The therapeutic index is wide, as high doses are generally well tolerated. Patients should be counselled regarding the risk of postural hypotension, effects of myocardial contractility, hypokalemia, hypomagnesemia, and hypoglycemia.
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Calcium Chelating Agents
Substances that bind to and sequester CALCIUM ions. (See all compounds classified as Calcium Chelating Agents.)
Food Additives
Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)
Route of Elimination
After intravenous administration, 95% of the dose is recovered in the urine after 24 hours. Oral administration in rats leads to 5.3% recovery in urine and 88.5% recovery in feces.
Volume of Distribution
Data regarding the volume of distribution of edetate disodium anhydrous is not readily available.
Clearance
The mean clearance of edetate in 1 month olds is 54.6mL/min/1.73m2. 2-17 year olds have a mean clearance of 113.9 24.4 mL/min/1.73m2.
After intravenous administration, the chelate formed is excreted in the urine with 50% appearing in 1 hour and over 95% in 24 hours.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
Disodium edentate ... /is/ poorly absorbed from the gastrointestinal tract and /is/ associated with few adverse effects when used as an excipient in pharmaceutical preparations.
Rowe, R.C., Sheskey, P.J., Quinn, M.E.; (Eds.), Handbook of Pharmaceutical Excipients 6th edition Pharmaceutical Press, London, England 2009, p. 243
Twenty male Sprague-Dawley rats were divided into four groups of five animals each. Rats in group 1 received ip injections of (14)C Disodium EDTA, group 2 received this compound on depilated skin, rats in group 3 received this compound on depilated and abraded skin (abraded every 2 or 3 cm over treated area), and group 4 was the control group. The specific activity of the (14)C Disodium EDTA was 21.6 mCi/mM and it was dissolved in saline to yield a final solution of 50 pCi/mL. Animals that received ip injections got 0.5 mL of this solution, or 25 pCi of (14)C Disodium EDTA. Animals that had the compound applied to the skin received 25 pCi of (14)C Disodium EDTA in the form of an ointment (modulan, mineral oil, petrolatum, cetyl alcohol 35:21 :25:12) spread over an area of 50 sq cm spread over a sheet of thin polyethylene. This sheet was taped to the trunk of each animal. A collar was fixed around the neck of the rats. All animals were decapitated 24 hours after treatment. The tissue distribution (per 100 mg wet organ weight) of (14)C Disodium EDTA 24 hours after ip administration was as follows: liver 577+/- 13, small intestine 631 +/- 25, large intestine 696 +/- 19, and kidney 1964 +/- 220. Twenty-four hours after application on normal skin the tissue distribution was as follows: liver 6 +/- 4, small intestine 99 +/- 22, large intestine 107 +/- 24, and kidneys 29 +/- 12. Twenty-four hours after application on abraded skin the tissue distribution was as follows: liver 139 +/- 34, small intestine 214 +/- 76, large intestine 309 +/- 115, and kidneys 222 +/- 30.
Cosmetic Ingredient Expert Review Panel; Final Final Report on the Safety Assessment of EDTA, Calcium, Disodium EDTA, Diammonium EDTA, Dipotassium EDTA, Disodium EDTA, TEA-EDTA, Tetrasodium EDTA, Tripotassium EDTA, Trisodium EDTA, HEDTA, and Trisodium HEDTA. International Journal of Toxicology 21 (S2): 95-142 (2002)
/Investigators/ reported that rats fed 0.5%, 1.0%, and 5.0% Disodium EDTA for 12 weeks excreted 82.2%, 44.5%, and 45.4%, respectively, of the ingested dose in the urine and feces. The feces contained 99.4%, 98.2%, and 97.5% of the excreted material and the urine contained 0.6%, 1.8%, and 2.5% of the material for the respective doses.
Cosmetic Ingredient Expert Review Panel; Final Final Report on the Safety Assessment of EDTA, Calcium, Disodium EDTA, Diammonium EDTA, Dipotassium EDTA, Disodium EDTA, TEA-EDTA, Tetrasodium EDTA, Tripotassium EDTA, Trisodium EDTA, HEDTA, and Trisodium HEDTA. International Journal of Toxicology 21 (S2): 95-142 (2002)
For more Absorption, Distribution and Excretion (Complete) data for Disodium EDTA (7 total), please visit the HSDB record page.
Edetate is almost completely unmetabolized _in vivo_.
After intravenous administration, the chelate formed is excreted in the urine with 50% appearing in 1 hour and over 95% in 24 hours.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
Edetate disodium anhydrous chelates divalent and trivalent ions such as magnesium, zinc, and calcium. The chelate is excreted in the urine, reducing concentrations of these ions in the blood.
Edetate disodium injection forms chelates with the cations of calcium and many divalent and trivalent metals. Because of its affinity for calcium, edetate disodium will produce a lowering of the serum calcium level during intravenous infusion. Slow infusion over a protracted period may cause mobilization of extracirculatory calcium stores. Edetate disodium exerts a negative inotropic effect upon the heart.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006).
Edetate disodium likewise forms chelates with other polyvalent metals and produces increases in urinary excretion of magnesium, zinc and other trace elements. It does not form a chelate with potassium but may reduce the serum level and increase urinary loss of potassium.
US Natl Inst Health; DailyMed. Current Medication Information for Endrate (edetate disodium, anhydrous) injection, solution (May 2006). Available from, as of February 16, 2012: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=290c3e9c-c0c6-440a-1a9c-46e3e2b07a77
API SUPPLIERS
Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-08-30
Pay. Date : 2022-08-03
DMF Number : 36993
Submission : 2022-07-13
Status : Active
Type : II
NDC Package Code : 62675-2350
Start Marketing Date : 2021-10-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-11-24
Pay. Date : 2020-10-22
DMF Number : 35275
Submission : 2020-10-01
Status : Active
Type : II
NDC Package Code : 68022-7059
Start Marketing Date : 2018-12-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10759
Submission : 1994-03-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10760
Submission : 1994-03-03
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.
Lead Product(s): Edetate Calcium Disodium,Citric Acid
Therapeutic Area: Podiatry Brand Name: Revye
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2024
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kane Biotech Receives FDA Approval to Increase Dosage of Revyve™ Wound Gel
Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.
Brand Name : Revye
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 23, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharma Hits Key Goals in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic...
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Details:
revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.
Lead Product(s): Edetate Calcium Disodium,Citric Acid
Therapeutic Area: Podiatry Brand Name: Revye
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Lead Product(s) : Edetate Calcium Disodium,Citric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve™ Antimicrobial Wound Gel at Ad...
Details : revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult po...
Brand Name : Revye
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 02, 2023
Details:
Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Lead Product(s): Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area: Infections and Infectious Diseases Brand Name: Elores
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2023
Lead Product(s) : Ceftriaxone,Edetate Calcium Disodium,Sulbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Venus Remedies Expands Reach with the Launch of Elores in Ecuador
Details : Elores, a cutting-edge antibiotic novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker) for complicated urinary tract infections.
Brand Name : Elores
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 14, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
Details : Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Details:
Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Lead Product(s): Edetate Calcium Disodium
Therapeutic Area: Pharmacology/Toxicology Brand Name: Edetate Calcium Disodium-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Lead Product(s) : Edetate Calcium Disodium
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Brand Name : Edetate Calcium Disodium-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Details:
The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and CLABSIs.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Mino-Lok
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 08, 2023
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : H.C. Wainwright & Co.
Deal Size : $15.0 million
Deal Type : Public Offering
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
Details : The net proceeds will be used to fund the company's pre-clinical and clinical development of its product candidates, including Mino-Lok® (minocycline), an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBS...
Brand Name : Mino-Lok
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2023
Details:
Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfactant.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Coactiv+
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Kane Biotech
Deal Size: Undisclosed Upfront Cash: $0.5 million
Deal Type: Agreement April 20, 2023
Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Kane Biotech
Deal Size : Undisclosed
Deal Type : Agreement
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its Coactiv+™ Antimicr...
Details : Under the agreement, ProgenaCare will commercialize coactiv+ (disodium EDTA) Antimicrobial Wound Gel in the U.S. wound care market. The coactiv+ is a combination of Kane’s patented coactiv+™ technology and PHMB, paired with a non-ionic pluronic surfa...
Brand Name : Coactiv+
Molecule Type : Small molecule
Upfront Cash : $0.5 million
April 20, 2023
Details:
The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.
Lead Product(s): Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Coactiv+
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Salud Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 04, 2023
Lead Product(s) : Edetate Calcium Disodium,Sodium Citrate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Salud Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Kane Biotech Announces First Distribution Agreement for its Coactiv+™ Antimicrobial Hydrogel
Details : The coactiv+™ (disodium EDTA) Antimicrobial Hydrogel is a combination of Kane’s patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.
Brand Name : Coactiv+
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Vials 0.5 G 5 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Ampoules 2 G 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Calcium Disodium Edetate
Dosage Form :
Dosage Strength : 5 Ampoules 1 G 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Calcium Disodium Edetate
Dosage Form :
Dosage Strength : 5 Ampoules 1 G 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Vials 0.5 G 5 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Vials 0.5 G 5 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Ampoules 2 G 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Disodium Edetate
Dosage Form :
Dosage Strength : 5 Ampoules 2 G 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
FDF DOSSIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
We have 4 companies offering Edetate Calcium Disodium
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
Market Place
